STAT+: FDA’s stronger warning on Sarepta gene therapy raises new questions about heart risk
New warnings and restrictions placed on Sarepta Therapeutics’ gene therapy last week by the Food and Drug Administration have cast a spotlight on an important but overlooked heart-safety risk.
“Acute, serious, and life-threatening” cases of heart inflammation called myocarditis and elevations of troponin-I, a protein released by dying heart-muscle cells, have been reported in patients treated with Elevidys, Sarepta’s gene therapy for Duchenne muscular dystrophy, according to its prescribing label updated on Friday.
A previous version of the Elevidys label noted only that “acute and serious” myocarditis and troponin-I elevations had been observed.
Adam Feuerstein and Jason Mast
Go to statnews